Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Company wins court ruling to continue development of Michigan factory serving EV industry
China honors promise to ensure smooth running of Chengdu Universiade: Xi
Russia says Moscow terror attack suspects planned to flee to Kiev for reward
A glimpse into Suzhou Industrial Park
Nadal returns to Roland Garros to practice amid doubts over fitness and form
Xi calls on Shaanxi to write new chapter in advancing Chinese modernization
12 die as bus falls into ditch in central India
With so many prospects playing well in the minors, Orioles GM has some tricky decisions ahead
Jessica Biel CHOPS her long locks into a bob after book signing in Studio City
Xi underlines prioritizing people's safety
Liverpool confirms Arne Slot as Jurgen Klopp's replacement
IOM assists in voluntary return of 133 Pakistanis from Libya